Evaluation of Intranasal Fentanyl and Midazolam Among Inpatient Pediatric Patients.

Q1 Nursing Hospital pediatrics Pub Date : 2024-10-01 DOI:10.1542/hpeds.2024-007819
Sriya Jampana, Laura C Harrison, Jessica McCall, Rebecca R Ferrante, Jeffery C Winer, Rudy John Kink, Nathaniel G Rogers
{"title":"Evaluation of Intranasal Fentanyl and Midazolam Among Inpatient Pediatric Patients.","authors":"Sriya Jampana, Laura C Harrison, Jessica McCall, Rebecca R Ferrante, Jeffery C Winer, Rudy John Kink, Nathaniel G Rogers","doi":"10.1542/hpeds.2024-007819","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The use of intranasal (IN) analgesics and sedatives has been studied among pediatrics patients in the emergency department and outpatient settings. However, less is known about their usage in inpatient settings. This study aims to evaluate the indications and safety profile for IN fentanyl and midazolam usage in pediatric patients admitted to a large tertiary care children's hospital.</p><p><strong>Methods: </strong>This study is a retrospective chart review of admitted patients receiving IN fentanyl and/or midazolam over a 6-year period. Indications for medication use, medication dosages, patient characteristics, and any serious adverse drug reactions were recorded. Reported serious adverse outcomes include use of reversal agents as well as any documented respiratory depression, hypotension, or need for escalation of care.</p><p><strong>Results: </strong>Of 156 patients included, 119 (76%) received IN midazolam alone, 20 (13%) patients received IN fentanyl alone, and 17 (11%) patients received both medications. The most common applications for IN medication administration were nasogastric tube placements (n = 62), peripheral intravenous line insertions (n = 30), peripherally-inserted central catheter placements (n = 23), and lumbar punctures (n = 16). No serious adverse events were reported.</p><p><strong>Conclusions: </strong>This study suggests that IN fentanyl and midazolam were administered to pediatric inpatients undergoing routine procedures without serious adverse drug reactions being reported. Although these findings are encouraging, more prospective studies are needed before wider implementation of IN fentanyl and midazolam administration in pediatric inpatients.</p>","PeriodicalId":38180,"journal":{"name":"Hospital pediatrics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1542/hpeds.2024-007819","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Nursing","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: The use of intranasal (IN) analgesics and sedatives has been studied among pediatrics patients in the emergency department and outpatient settings. However, less is known about their usage in inpatient settings. This study aims to evaluate the indications and safety profile for IN fentanyl and midazolam usage in pediatric patients admitted to a large tertiary care children's hospital.

Methods: This study is a retrospective chart review of admitted patients receiving IN fentanyl and/or midazolam over a 6-year period. Indications for medication use, medication dosages, patient characteristics, and any serious adverse drug reactions were recorded. Reported serious adverse outcomes include use of reversal agents as well as any documented respiratory depression, hypotension, or need for escalation of care.

Results: Of 156 patients included, 119 (76%) received IN midazolam alone, 20 (13%) patients received IN fentanyl alone, and 17 (11%) patients received both medications. The most common applications for IN medication administration were nasogastric tube placements (n = 62), peripheral intravenous line insertions (n = 30), peripherally-inserted central catheter placements (n = 23), and lumbar punctures (n = 16). No serious adverse events were reported.

Conclusions: This study suggests that IN fentanyl and midazolam were administered to pediatric inpatients undergoing routine procedures without serious adverse drug reactions being reported. Although these findings are encouraging, more prospective studies are needed before wider implementation of IN fentanyl and midazolam administration in pediatric inpatients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对住院儿科患者鼻内注射芬太尼和咪达唑仑的评估
目的:已经对急诊科和门诊儿科病人使用鼻内镇痛剂和镇静剂的情况进行了研究。然而,人们对其在住院环境中的使用却知之甚少。本研究旨在评估一家大型三甲儿童医院收治的儿科患者使用 IN 芬太尼和咪达唑仑的适应症和安全性:本研究是一项回顾性病历审查,涉及 6 年间接受 IN 芬太尼和/或咪达唑仑治疗的入院患者。研究记录了用药指征、用药剂量、患者特征以及任何严重的药物不良反应。报告的严重不良反应包括使用逆转剂以及任何记录在案的呼吸抑制、低血压或护理升级需求:在纳入的 156 例患者中,119 例(76%)患者仅接受了咪达唑仑 IN,20 例(13%)患者仅接受了芬太尼 IN,17 例(11%)患者同时接受了两种药物。最常见的 IN 给药应用是鼻胃管置入(62 例)、外周静脉置管(30 例)、外周置入中心导管(23 例)和腰椎穿刺(16 例)。无严重不良事件报告:本研究表明,对接受常规手术的儿科住院患者使用 IN 芬太尼和咪达唑仑时,未报告严重的药物不良反应。尽管这些研究结果令人鼓舞,但在儿科住院患者中更广泛地使用IN芬太尼和咪达唑仑之前,还需要进行更多的前瞻性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hospital pediatrics
Hospital pediatrics Nursing-Pediatrics
CiteScore
3.70
自引率
0.00%
发文量
204
期刊最新文献
A National Analysis of General Pediatric Inpatient Unit Closures and Openings, 2011-2018. Are Children's Hospitals Doing Enough to Address the Climate Crisis? A Mandate to Mitigate Bias. Potential Bias in Social Work Consultations in the Pediatric Inpatient Setting. Are Child Access Prevention Laws Associated With Fewer Pediatric Firearm Injuries?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1